<DOC>
	<DOCNO>NCT01555710</DOCNO>
	<brief_summary>This multinational , multicenter , randomize control , open-label , adaptive study evaluate efficacy PaCE chemotherapy chemotherapy naive subject extensive-stage SCLC . Eligible subject stratify accord age , gender , Eastern Cooperative Oncology Group ( ECOG ) performance status , randomize 1:1 ratio receive either PaCE CE chemotherapy . The study design use adaptive group sequential approach sample size re-estimation interim analysis . Secondary efficacy endpoint include ORR , PFS , duration response change QOL disease-related symptom . Tumor-related endpoint assess accord Response Evaluation Criteria Solid Tumors ( RECIST ) v1.1 guideline . The safety study treatment assess frequency severity adverse event determine National Cancer Institute ( NCI ) Common Terminology Criteria Adverse Events ( CTCAE ) v4.03 . To provide initial confirmation safety , early interim analysis safety data perform . An independent Data Monitoring Committee ( DMC ) convene assess safety efficacy study intervention monitor overall conduct clinical trial .</brief_summary>
	<brief_title>Study Palifosfamide-tris Combination With Carboplatin Etoposide Chemotherapy Na√Øve Patients With Extensive-Stage Small Cell Lung Cancer ( The MATISSE Study )</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<criteria>Documented extensivestage small cell lung cancer . Patient receive prior chemotherapy , adjuvant therapy , radiotherapy lung cancer . ECOG Performance Status 0 , 1 2 . Adequate bone marrow organ function base result protocol specified laboratory test . Male female patient must agree use highly reliable method birth control study participation . Able provide inform consent Previously untreated ( nonirradiated ) , symptomatic brain metastasis . Known allergy study drug excipients . Any unstable clinically significant concurrent medical condition would , opinion investigator , jeopardize safety patient and/or compliance protocol , base screening test , physical examination medical history ( specifically define clinical protocol ) . Any malignancy small cell lung cancer within last 5 year prior randomization , exception cervical carcinoma situ , nonmelanoma skin cancer , superficial bladder tumor ( Ta , Tis , T1 ) successfully curatively treated evidence recurrent residual disease . ( Exception : Subjects history malignancy small cell lung cancer may enrol consultation medical monitor provide patient 's prognosis best defined extensivestage small cell lung cancer ) . Currently pregnant nursing .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
</DOC>